Europe needs to be better prepared for the coming autumn and winter seasons to avoid medicine shortages like those experienced this year, the EU’s Health Commissioner Stella Kyriakides warned.

The colder months are often challenging for drug supplies, as cases of respiratory illness and influenza tend to spike across the bloc.

However, the recent winter brought particular problems for Europe, with a marked rise in respiratory infections and continued cases of COVID-19 causing a spike in demand for antibiotics and painkillers.

A particular cause of headaches was the short supply of amoxicillin, an antibiotic used to treat bacterial infections.

This circumstance must be avoided in the coming years, EU health chief Stella Kyriakides told MEPs in the first official meeting of the newly-set European Parliament’s health sub-committee (SANT) on Thursday (20 April).

“We need to be better prepared for next autumn and winter,” she said, assuring lawmakers that the European Commission is already working with the European Medicine Agency (EMA) to secure the availability of key antibiotics for next year.

The role of HERA

One way of mitigating potential shortages could be through stockpiling with the European Health Emergency Preparedness and Response Authority (HERA), Kyriakides said.

HERA, a directorate-general of the EU executive, was established after the outbreak of the COVID-19 pandemic, to prevent and respond rapidly to future health emergencies.

In the SANT debate, lawmakers insisted that member states and stakeholders must continue to collaborate in order to address health at the EU level.

Kyriakides replied that, while many health issues remain of national competence, the Commission is engaging with the different national authorities and with industry in order to have a way to address this common challenge.

“We need to have a coordinated approach between the member states and use what we have learned from the pandemic,” she continued.

She cited joint procurement as an example of a mechanism used during the COVID-19 pandemic that HERA is considering applying in other situations.

According to Kyriakides, discussions are ongoing about the use of joint procurement for avian flu.

Upcoming pharmaceutical legislation
Availability, accessibility, and affordability of medicines are key concerns that will be addressed by the reform of EU’s pharmaceutical legislation – which is due to be presented after several delays next week (26 April).

The revamping of the EU’s general legislation on medicines for human use is the last major health file to be unveiled by the EU executive before the end of the current legislative term in the second half of 2024.

Kyriakides said that this initiative will aim at ensuring a future-proof and crisis-resistant medicines regulatory system for Europe while continuing to foster innovation so the pharmaceutical industry “remains a world-class innovator”.

She insisted that access to medicines is a political priority because “there cannot be first and second-class citizens in the EU”.

“All of us deserve to have timely and equal access to medicines,” she concluded.

Source: Euractiv.com